Complement-regulatory proteins in ovarian malignancies

International Journal of Cancer

Volumn 70, Issue 1, 1997, Pages 14-25

  Bjørge, Line ^a,c   Hakulinen, Juha ^a   Wahlström, Torsten ^b   Matre, Roald ^c   Meri, Seppo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL DESTRUCTION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; CA-19-9 ANTIGEN; FEMALE; FLOW CYTOMETRY; HUMANS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, FLUORESCENCE; OVARIAN NEOPLASMS; RATS; RECEPTORS, COMPLEMENT; RNA, MESSENGER; RNA, NEOPLASM; TERATOCARCINOMA; TUMOR CELLS, CULTURED;

EID: 0031018621     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9     Document Type: Article

References (21)

1. BALLARD, L., SEYA, T., TECKMAN, J., LUBLIN, D.M. and ATKINSON, J.P., Polymorphism of the complement regulatory protein MCP (membrane co-factor protein or gp45-70). J. Immunol., 138, 3850-3855 (1987).
2. CHAPMAN, P.B., SCHEINBERG, D.A., DIMAGGIO, J.J. and HOUGHTON, A.N., Unconjugated monoclonal antibodies as cancer agents. Immunol. Allergy Clin. North Amer., 11, 257-275 (1991).
3. CHEUNG, N.K., WALTER, E.I., SMITH-MENSAH, W.H., RATNOFF, W.D., TYKOCINSKI, M.L. and MEDOF, M.E., Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. clin. Invest., 81, 1122-1128 (1988).
4. DAVIES, A., SIMMONS, D.L., HALE, G., HARRISON, R.A., TIGHE, H., LACHMANN, P.J. and WALDMANN, H., CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement-membrane-attack complex on homologous cells. J. exp. Med., 170, 637-654 (1989).
5. FRIEDLANDER, M.L. and DEMBO, A.J., Prognostic factors in ovarian cancer. Semin. Oncol., 18, 205-212 (1991).
6. HAKULINEN, J. and MERI, S., Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab. Invest., 71, 820-827 (1994).
7. JACOBS, I. and BAST, R.C. JR., The CA-125 tumour-associated antigen: a review of the literature. Hum. Reprod., 4, 1-12 (1989).
8. KORETZ, K., BRÜDERLEIN, S., HENNE, C. and MÖLLER, P., Expression of CD59, a complement-regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Brit. J. Cancer, 68, 926-931 (1993).
9. MÄENPÄÄ, A., JUNNIKKALA, S., HAKULINEN, J., TlMONEN, T. and MERI, S., Expression of complement membrane regulators, membrane co-factor protein (CD46), decay-accelerating factor (CD55) and protectin (CD59) in human malignant gliomas. Amer. J. Pathol., 148, 1139-1152 (1996).
10. MEDOF, M.E., WALTER, E.I., RUTGERS, J.L., KNOWLES, D.M. and NUSSENZWEIG, V., Identification of the complement-decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. exp. Med., 165, 848-864 (1987).
11. MERI, S., LEHTO, T., SUTTON, C.W., TYYNELÄ, J. and BAUMANN, M., Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass-spectrometric analysis. Biochem. J., 316, 923-935 (1996).
12. MERI S., MORGAN, B.P., DAVIES, A., DANIELS, R.H., OLAVESEN, M.G., WALDMANN, H., and LACHMANN, P.J., Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology, 71, 1-9 (1990).
13. MORGAN, B.P., Effects of the membrane attack complex of complement on nucleated cells. Curr. Top. Microbiol. Immunol., 178, 115-140 (1992).
14. MORGAN, B.P. and MERI, S.,Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol., 15, 369-396 (1994).
15. MUTO, M.G. and KASSIS, A.I., Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Cancer, 76, 2016-2027 (1995).
16. PARKIN, D.M., LÄÄRÄ, E. and MUIR, C.S., Estimation of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer, 15, 184-197 (1988).
17. ROBERTS, W.L., MYHER, J.J., KUKSIS, A., Low, M.G. and ROSENBERRY, T.L., Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. Palmitoylation of inositol results in resistance to phosphatidylinositol-specific phospholipase C. J. biol. Chem., 263, 18766-18775 (1988).
18. ROLLINS, S.A. and SIMS, P.J., The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol., 144, 3478-3483 (1990).
19. RUBIN, S.C., Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. Cancer. 71, 1602-1612 (1993).
20. SUGITA, Y., NAKANO, Y. and TOMITA, M., Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J. Biochem., 104, 633-637 (1988).
21. YAMAKAWA, M., YAMADA, K., TSUGE, T., OHRUI, H., OGATA, T., DOBASHI, M. and IMAI, Y., Protection of thyroid cancer cells by complement-regulatory factors. Cancer, 73, 2808-2817 (1994).